Clinical Study
Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
Table 2
Fluorescein angiographic findings after primary intravitreal conbercept or ranibizumab in neonates with ROP.
| | Group | Patient no. | Diagnosis | GA, weeks | BW, g | PMA at FA, weeks | Eyes | Injection times | Fluorescein angiography findings | | Avascular zone | Leakage | Blunting | Dilation | Loops | Arteriovenous shunt | Capillary dropout |
| | C | 1 | Zone II
Stage 3+ | 28 | 1080 | 94.14 | OD | 2 | Y | Y | Y | Y | Y | N | Y | | OS | 2 | Y | Y | Y | Y | Y | Y | N | | C | 2 | Zone II
Stage 3+ | 26.14 | 937 | 98.86 | OD | 2 | Y | N | Y | Y | Y | Y | Y | | OS | 2 | Y | Y | Y | Y | Y | N | Y | | C | 3 | Zone II
Stage 3+ | 28 | 1175 | 85.86 | OD | 1 | N | N | Y | N | N | N | N | | OS | 1 | Y | N | Y | Y | Y | Y | Y | | C | 4 | Zone II
Stage 3+ | 28 | 1360 | 90.86 | OD | 1 | Y | N | Y | Y | N | Y | Y | | OS | 1 | Y | N | Y | Y | N | Y | Y | | C | 5 | Zone II
Stage 3+ | 28.43 | 850 | 82.57 | OD | 2 | Y | N | Y | Y | Y | N | Y | | OS | 2 | Y | N | Y | Y | Y | N | Y | | C | 6 | Zone II
Stage 3+ | 29.43 | 850 | 84.71 | OD | 1 | Y | N | N | N | N | N | Y | | OS | 1 | Y | N | Y | Y | Y | N | Y | | C | 7 | Zone II
Stage 3+ | 26.86 | 920 | 76.86 | OD | 2 | Y | N | Y | N | Y | N | Y | | OS | 2 | Y | N | Y | Y | Y | Y | N | | C | 8 | Zone II
Stage 3+ | 29.29 | 1550 | 80.57 | OD | 1 | Y | N | Y | N | N | N | Y | | OS | 1 | Y | N | Y | N | Y | Y | Y | | C | 9 | Zone II
Stage 3+ | 26.43 | 1010 | 71.29 | OD | 1 | Y | N | Y | Y | Y | N | N | | OS | 1 | Y | N | Y | Y | Y | N | N | | C | 10 | Zone II
Stage 3+ | 34 | 860 | 92.14 | OD | 1 | Y | N | Y | Y | N | N | Y | | OS | 1 | Y | Y | Y | Y | Y | Y | Y | | C | 11 | Zone II
Stage 3+ | 33.43 | 2100 | 115.43 | OD | 1 | Y | Y | Y | Y | Y | N | N | | OS | 1 | Y | N | Y | Y | Y | Y | Y | | C | 12 | Zone II
Stage 3+ | 30.29 | 1350 | 95.29 | OD | 1 | Y | N | Y | Y | Y | N | Y | | OS | 1 | Y | N | Y | N | Y | N | Y | | C | 13 | AP-ROP | 29.43 | 1200 | 93.57 | OD | 1 | Y | N | Y | N | Y | Y | Y | | OS | 1 | Y | Y | Y | N | Y | Y | Y | | C | 14 | Zone II
Stage 3+ | 26.43 | 890 | 78 | OD | 1 | Y | N | Y | Y | Y | Y | N | | OS | 1 | Y | Y | Y | Y | Y | Y | N | | C | 15 | Zone II
Stage 3+ | 30.29 | 1400 | 95.29 | OD | 1 | Y | N | Y | Y | Y | Y | N | | R | 1 | Zone II
Stage 3+ | 28.29 | 1100 | 66.29 | OD | 2 | Y | N | Y | Y | Y | Y | N | | OS | 2 | Y | Y | Y | Y | Y | N | Y | | R | 2 | Zone II
Stage 3+ | 27.71 | 1150 | 65.57 | OD | 1 | Y | Y | Y | Y | Y | Y | Y | | OS | 1 | Y | Y | Y | Y | Y | N | Y | | R | 3 | Zone II
Stage 3+ | 27.43 | 1100 | 71.57 | OD | 1 | Y | Y | Y | Y | Y | Y | N | | OS | 1 | Y | Y | Y | N | Y | N | Y | | R | 4 | Zone II
Stage 3+ | 28.43 | 1190 | 110.86 | OD | 1 | Y | N | Y | Y | N | N | Y | | OS | 1 | Y | N | Y | Y | N | N | Y | | R | 5 | Zone II
Stage 3+ | 26.29 | 1000 | 71.57 | OD | 1 | Y | N | Y | N | Y | N | N | | OS | 2 | Y | Y | Y | Y | N | N | Y | | R | 6 | Zone II
Stage 2+ | 28.86 | 1250 | 116.71 | OD | 1 | Y | N | Y | N | N | N | N | | OS | 1 | Y | N | Y | Y | Y | Y | N | | R | 7 | Zone II
Stage 3+ | 27.86 | 1070 | 70.86 | OD | 3 | Y | N | Y | Y | Y | N | Y | | OS | 3 | Y | Y | Y | Y | Y | Y | N | | R | 8 | Zone II
Stage 3+ | 25.43 | 900 | 133.71 | OD | 2 | Y | N | Y | Y | N | Y | N | | OS | 2 | Y | N | Y | N | N | N | Y | | R | 9 | Zone II Stage 3+ | 27.86 | 760 | 120.29 | OD | 1 | N | N | Y | N | N | N | N | | Zone II Stage 2+ | OS | 1 | Y | N | Y | N | N | N | Y | | R | 10 | AP-ROP | 32.57 | 1950 | 110 | OD | 1 | Y | N | Y | Y | Y | Y | Y | | OS | 2 | Y | Y | Y | N | Y | N | N | | R | 11 | AP-ROP | 29.57 | 1500 | 122.86 | OD | 2 | Y | N | Y | Y | Y | Y | Y | | OS | 2 | Y | N | Y | N | Y | Y | Y | | R | 12 | AP-ROP | 33.43 | 1900 | 95.43 | OD | 2 | N | Y | Y | N | Y | N | Y | | OS | 2 | Y | N | Y | N | N | N | Y | | R | 13 | Zone II Stage2+ | 30.14 | 1445 | 118.57 | OD | 1 | Y | Y | Y | Y | Y | N | Y |
|
|
Group C, treated with conbercept; Group R, treated with ranibizumab; GA, gestational age; BW, birth weight; PMA, postmenstrual age; FA, fluorescein angiography; AP-ROP, aggressive posterior retinopathy of prematurity.
|
